FDA Fast-Tracks Faron’s Bexmarilimab for r/r MDS

Faron Pharmaceuticals Oy (GB:FARN) has released an update.

Faron Pharmaceuticals Oy has announced that the FDA has granted Fast Track Designation to their drug candidate bexmarilimab for the treatment of relapsed or refractory myelodysplastic syndrome (r/r MDS), in combination with azacitidine. This designation, which expedites the development and review of drugs for serious conditions and unmet medical needs, follows promising results from early-phase trials. The company believes that bexmarilimab has the potential to become a new cornerstone treatment for r/r MDS, a condition with very limited treatment options and a high mortality rate.

For further insights into GB:FARN stock, check out TipRanks’ Stock Analysis page.